These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33210958)

  • 41. Thrombin-derived C-terminal fragments aggregate and scavenge bacteria and their proinflammatory products.
    Petrlova J; Petruk G; Huber RG; McBurnie EW; van der Plas MJA; Bond PJ; Puthia M; Schmidtchen A
    J Biol Chem; 2020 Mar; 295(11):3417-3430. PubMed ID: 32034093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotic-induced endotoxin release from bacteria and its clinical significance.
    Kirikae T; Nakano M; Morrison DC
    Microbiol Immunol; 1997; 41(4):285-94. PubMed ID: 9159401
    [No Abstract]   [Full Text] [Related]  

  • 43. Co-administration of phospholipid emulsion with first dose bacteriocidal antibiotic may retard progression of the sepsis response in gram negative septicaemia.
    Harvey M; Cave G
    Med Hypotheses; 2014 Nov; 83(5):563-5. PubMed ID: 25225084
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.
    Opal SM; Yu RL
    Drugs; 1998 Apr; 55(4):497-508. PubMed ID: 9561340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 47. C1 inhibitor suppresses the endotoxic activity of a wide range of lipopolysaccharides and interacts with live gram-negative bacteria.
    Mejia P; Davis AE
    Shock; 2012 Aug; 38(2):220-5. PubMed ID: 22576004
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-endotoxin mechanism of the KW4 peptide in inflammation in RAW 264.7 cells induced by LTA and drug-resistant Staphylococcus aureus 1630.
    Lee JK; Park Y
    Amino Acids; 2018 Apr; 50(3-4):363-372. PubMed ID: 29238856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.
    El Chakhtoura NG; Saade E; Iovleva A; Yasmin M; Wilson B; Perez F; Bonomo RA
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):89-110. PubMed ID: 29310479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria.
    Jean SS; Hsueh SC; Lee WS; Hsueh PR
    Expert Rev Anti Infect Ther; 2019 May; 17(5):307-309. PubMed ID: 31055983
    [No Abstract]   [Full Text] [Related]  

  • 51. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
    Mullarkey M; Rose JR; Bristol J; Kawata T; Kimura A; Kobayashi S; Przetak M; Chow J; Gusovsky F; Christ WJ; Rossignol DP
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1093-102. PubMed ID: 12604686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endotoxins: relationships between structure, function, and activity.
    Brandenburg K; Wiese A
    Curr Top Med Chem; 2004; 4(11):1127-46. PubMed ID: 15279605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria.
    Yethon JA; Whitfield C
    Curr Drug Targets Infect Disord; 2001 Aug; 1(2):91-106. PubMed ID: 12455407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. JAK2-STAT Epigenetically Regulates Tolerized Genes in Monocytes in the First Encounter With Gram-Negative Bacterial Endotoxins in Sepsis.
    Morante-Palacios O; Lorente-Sorolla C; Ciudad L; Calafell-Segura J; Garcia-Gomez A; Català-Moll F; Ruiz-Sanmartín A; Martínez-Gallo M; Ferrer R; Ruiz-Rodriguez JC; Álvarez-Errico D; Ballestar E
    Front Immunol; 2021; 12():734652. PubMed ID: 34867954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibiotic-mediated release of endotoxin and the pathogenesis of gram-negative sepsis.
    Morrison DC
    Prog Clin Biol Res; 1998; 397():199-207. PubMed ID: 9575560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens.
    Song M; Liu Y; Huang X; Ding S; Wang Y; Shen J; Zhu K
    Nat Microbiol; 2020 Aug; 5(8):1040-1050. PubMed ID: 32424338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular biology of endotoxin antagonism.
    Lazaron V; Dunn DL
    World J Surg; 2002 Jul; 26(7):790-8. PubMed ID: 11948366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Condie RM; Cerra FB
    Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimicrobial peptide rBPI21: a translational overview from bench to clinical studies.
    Domingues MM; Santos NC; Castanho MA
    Curr Protein Pept Sci; 2012 Nov; 13(7):611-9. PubMed ID: 23116442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthetic high-density lipoprotein-like nanoparticles potently inhibit cell signaling and production of inflammatory mediators induced by lipopolysaccharide binding Toll-like receptor 4.
    Foit L; Thaxton CS
    Biomaterials; 2016 Sep; 100():67-75. PubMed ID: 27244690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.